These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1144 related items for PubMed ID: 28213001

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
    Lin JH, Lin D, Xu L, Wang Q, Hu HH, Xu HP, He ZY.
    Oncotarget; 2017 Jan 10; 8(2):3412-3421. PubMed ID: 27926500
    [Abstract] [Full Text] [Related]

  • 4. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
    Hasegawa Y, Ando M, Maemondo M, Yamamoto S, Isa S, Saka H, Kubo A, Kawaguchi T, Takada M, Rosell R, Kurata T, Ou SH.
    Oncologist; 2015 Mar 10; 20(3):307-15. PubMed ID: 25657199
    [Abstract] [Full Text] [Related]

  • 5. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival.
    Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC.
    J Natl Cancer Inst; 2017 Jun 01; 109(6):. PubMed ID: 28376144
    [Abstract] [Full Text] [Related]

  • 6. Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.
    Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF.
    Eur J Cancer; 2011 Nov 01; 47(17):2603-6. PubMed ID: 21784628
    [Abstract] [Full Text] [Related]

  • 7. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q, Ke E, Niu F, Deng W, Chen Z, Xu C, Zhang X, Zhao N, Su J, Yang J, Yan H, Wu Y, Zhou Q.
    Oncotarget; 2017 Jan 17; 8(3):4994-5002. PubMed ID: 27999211
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis.
    Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, Lee SH, Heo DS.
    JAMA; 2014 Apr 09; 311(14):1430-7. PubMed ID: 24715074
    [Abstract] [Full Text] [Related]

  • 10. Impact of Continuing First-Line EGFR Tyrosine Kinase Inhibitor Therapy Beyond RECIST Disease Progression in Patients with Advanced EGFR-Mutated Non-Small-Cell Lung Cancer (NSCLC): Retrospective GFPC 04-13 Study.
    Auliac JB, Fournier C, Audigier Valette C, Perol M, Bizieux A, Vinas F, Decroisette Phan van Ho C, Bota Ouchlif S, Corre R, Le Garff G, Fournel P, Baize N, Lamy R, Vergnenegre A, Arpin D, Marin B, Chouaid C, Gervais R.
    Target Oncol; 2016 Apr 09; 11(2):167-74. PubMed ID: 26315967
    [Abstract] [Full Text] [Related]

  • 11. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M, Okamoto I, Tsurutani J, Oiso N, Kawada A, Nakagawa K.
    Jpn J Clin Oncol; 2012 Jun 09; 42(6):528-33. PubMed ID: 22457323
    [Abstract] [Full Text] [Related]

  • 12. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K, Hata A, Takeshita J, Okuda C, Kaji R, Masago K, Fujita S, Katakami N.
    Cancer Chemother Pharmacol; 2015 Oct 09; 76(4):835-41. PubMed ID: 26349474
    [Abstract] [Full Text] [Related]

  • 13. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903).
    Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y, North-East Japan Study Group.
    Lung Cancer; 2014 Nov 09; 86(2):195-200. PubMed ID: 25249428
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. EGFR-TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation.
    Koo DH, Kim KP, Choi CM, Lee DH, Lee JC, Lee JS, Jang SJ, Kim SW.
    Cancer Chemother Pharmacol; 2015 Jan 09; 75(1):197-206. PubMed ID: 25422153
    [Abstract] [Full Text] [Related]

  • 16. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL, Heideman DA, Thunnissen E, Paul MA, van Wijk AW, Postmus PE, Smit EF.
    Lung Cancer; 2014 Jul 09; 85(1):19-24. PubMed ID: 24768581
    [Abstract] [Full Text] [Related]

  • 17. [Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].
    Fan Y, Huang ZY, Yu HF, Luo LH.
    Zhonghua Zhong Liu Za Zhi; 2010 Nov 09; 32(11):859-63. PubMed ID: 21223694
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials.
    Gao G, Ren S, Li A, Xu J, Xu Q, Su C, Guo J, Deng Q, Zhou C.
    Int J Cancer; 2012 Sep 01; 131(5):E822-9. PubMed ID: 22161771
    [Abstract] [Full Text] [Related]

  • 19. Sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors in males, smokers, and non-adenocarcinoma lung cancer in patients with EGFR mutations.
    Zeng Z, Chen HJ, Yan HH, Yang JJ, Zhang XC, Wu YL.
    Int J Biol Markers; 2013 Sep 27; 28(3):249-58. PubMed ID: 23873621
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 58.